Author:
Boidot Romain,Blum Michael G.B.,Wissler Marie-Pierre,Gottin Céline,Ruzicka Jiri,Chevrier Sandy,Delhomme Tiffany M.,Audoux Jérome,Jeanniard Adrien,Just Pierre-Alexandre,Harter Philipp,Pignata Sandro,González-Martin Antonio,Marth Christian,Mäenpää Johanna,Colombo Nicoletta,Vergote Ignace,Fujiwara Keiichi,Duforet-Frebourg Nicolas,Bertrand Denis,Philippe Nicolas,Ray-Coquard Isabelle,Pujade-Lauraine Eric
Reference34 articles.
1. Global cancer observatory: cancer today;Ferlay,2018
2. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial;Banerjee;Lancet Oncol,2021
3. Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer;Coleman;N Engl J Med Mass Med Soc,2019
4. Niraparib in patients with newly diagnosed advanced ovarian cancer;González-Martín;N Engl J Med Mass Med Soc,2019
5. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial;Moore;Lancet Oncol,2019